EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction

Brendan T Frainey, Douglass B Clayton

Frontiers in Pediatrics · 03.06.2024 · 12

DOI: 10.3389/fped.2024.1407009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 03.06.2024. Verfasst von Brendan T Frainey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Division of Pediatric Urology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nash…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Initial urologic management of pediatric neurogenic lower urinary tract dysfunction (NLUTD) includes clean intermittent catheterization (CIC) regimen and use of anticholinergic or beta3 agonist medications. Historically, NLUTD that did not respond to these initial management strategies received open surgical procedures such as augmentation cystoplasty (AC) to increase bladder capacity and create a lower-pressure reservoir. Since its first reported use in 2002, intradetrusor onabotulinumtoxinA (BTX-A) injections has developed an emerging role in management of pediatric NLUTD, culminating in its recent FDA-approval in 2021. In this review, the current evidence regarding the safety, tolerability, and efficacy of BTX-A use in pediatric NLUTD will be summarized. Additionally, we will attempt to define the current role of BTX-A in the management of patients with NLUTD, discuss limitations to the current body of literature, and suggest future avenues of study.

Schlagwörter

Stichwörter der Autor:innen

managementmyelomeningoceleneurogenic bladderonabotulinumtoxinApediatric urology

Autor:innen und Institutionen

  • Department of Urology, Division of Pediatric Urology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN, United States.

Zitieren

APA

Frainey, B. T., & Clayton, D. B. (2024). OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction. Frontiers in Pediatrics, 12. https://doi.org/10.3389/fped.2024.1407009

Vancouver

Frainey BT, Clayton DB. OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction. Frontiers in Pediatrics. 2024;12. doi:10.3389/fped.2024.1407009

BibTeX
@article{Frainey2024,
  author = {Frainey, Brendan T and Clayton, Douglass B},
  title = {OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction},
  journal = {Frontiers in Pediatrics},
  year = {2024},
  volume = {12},
  doi = {10.3389/fped.2024.1407009}
}
Kostenlos starten →